Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

European Journal of Cancer

Volumn 49, Issue 18, 2013, Pages 3780-3787

  Castellano, Daniel ^a   Capdevila, Jaume ^b   Sastre, Javier ^c   Alonso, Vicente ^d   Llanos, Marta ^e   García Carbonero, Rocío ^f   Manzano Mozo, José Luis ^g   Sevilla, Isabel ^h   Durán, Ignacio ⁱ   Salazar, Ramón ^j  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h Hospital Clínico   (Spain)

ⁱ Hospital Madrid Norte Sanchinarro   (Spain)

^j CATALAN INSTITUTE OF ONCOLOGY   (Spain)

more..

Author keywords

Bevacizumab; Sorafenib; Targeted therapy

Indexed keywords

BEVACIZUMAB; SOMATOSTATIN DERIVATIVE; SORAFENIB;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTERY THROMBOSIS; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOID; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHONIA; EPISTAXIS; FEMALE; HAND FOOT SYNDROME; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREAS TUMOR; PHASE 2 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; RASH; SIDE EFFECT; TREATMENT RESPONSE; VOMITING;

BEVACIZUMAB; SORAFENIB; TARGETED THERAPY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUCOSITIS; NEUROENDOCRINE TUMORS; NIACINAMIDE; PHENYLUREA COMPOUNDS; SPAIN; TREATMENT OUTCOME;

EID: 84888009143     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.06.042     Document Type: Article

References (34)

1. D. Castellano Gastroenteropancreatic neuroendocrine tumors. Where are we now? Cancer Metastasis Rev 30 Suppl. 1 2011 s1
2. K. Oberg Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NETs) Rocz Akad Med Bialymst 50 2005 62 68
3. I.M. Modlin, K.D. Lye, and M. Kidd A 5-decade analysis of 13715 carcinoid tumors Cancer 97 2003 934 959
4. J.C. Reubi Peptide receptors as molecular targets for cancer diagnosis and therapy Endocr Rev 24 2003 389 427
5. I.M. Modlin, M. Pavel, and M. Kidd Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours Aliment Pharmacol Ther 31 2 2010 169 188
6. A. Rinke, H. Müller, and C. Schade-Brittinger Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group J Clin Oncol 27 2009 4656 4663
7. C.G. Moertel, M. Lefkopoulo, S. Lipsitz, R.G. Hahn, and D. Klaassen Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma N Engl J Med 326 1992 519 523
8. E. Raymond, T. Hobday, and D. Castellano Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors Cancer Metastasis Rev 30 Suppl. 1 2011 S19 S26
9. D.E. Hansel, A. Rahman, and J. Hermans Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression Mod Pathol 16 7 2003 652 659
10. M.L. Fjällskog, M.H. Lejonklou, K.E. Oberg, B.K. Eriksson, and E.T. Janson Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors Clin Cancer Res 9 4 2003 1469 1473
11. J.C. Yao, A. Phan, and P.M. Hoff Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b J Clin Oncol 26 8 2008 1316 1323
12. T.J. Hobday, J. Rubin, and K. Holen MC044h, a phase II trial of sorafenib in patients with metastatic neuroendocrine tumors (NET): A phase II consortium study J Clin Oncol 25 2007 18s [Suppl.; abstr 4504]
13. M.H. Kulke, H.J. Lenz, and N.J. Meropol A phase 2 study to evaluate the efficacy and safety of SU11248 in patients with unresectable neuroendocrine tumors (NETs) J Clin Oncol 23 2005 310s [Suppl.: abstr 4008]
14. E. Raymond, L. Dahan, and J. Raoul Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 2011 501 513
15. D. Castellano, E. Grande, J. Barriuso, L. Antón-Aparicio, and D. Castellano Advances in pancreatic neuroendocrine tumor treatment N Engl J Med 364 2011 1871 1875
16. E. Grande Pulido, D. Castellano, and R. Garcia-Carbonero PAZONET: Results of a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs (GETNE) - NCT01280201 J Clin Oncol 30 2012 [Suppl.; abstr 4119]
17. I. Duran, J. Kortmansky, and D. Singh A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinoma Br J Cancer 95 2006 1148 1154
18. E.F. Petricoin, K.C. Zoon, and E.C. Kohn Clinical proteomics: translating benchside promise into bedside reality Nat Rev Drug Discov 1 2002 683 695
19. N.S. Azad, E.M. Posadas, and V.E. Kwitkowski Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity J Clin Oncol 26 22 2008 3709 3714
20. J.A. Sosman, K. Flaherty, and M.B. Atkins A phase I/II trial of sorafenib with bevacizumab in metastatic renal cell cancer patients J Clin Oncol 24 Suppl. 2006 18 [abstr 3031]
21. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
22. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS. March 31; 2003. Avaliable from: http://ctep.cancer.gov [publish date 09.09.06].
23. J.C. Yao, A.T. Phan, and D. Fogleman Randomized run-in study of bevacizumab (B) and everolimus (E) in low-to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker J Clin Oncol 28 2010 15s [abstr 4002]
24. D. Mahalingam, M. Beeram, and J. Rodon Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab (B) in combination with sorafenib (S) in patients (pts) with advanced malignant melanoma J Clin Oncol 2010 [Suppl.; abstr e19008]
25. A. Grothey, J.M. Lafky, and B.W. Morlan Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): Results of the phase II North Central Cancer Treatment Group study N054C J Clin Oncol 28 2010 15s [Suppl.; abstr 3549]
26. M.E. Pavel, G. Hassler, and U. Baum Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas Clin Endocrinol (Oxf) 62 2005 434 443
27. J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, and E. Van Cutsem Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
28. M.E. Pavel, J.D. Hainsworth, and E. Baudin Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Lancet 378 2011 2005 2012
29. J.C. Yao, T.P. Phan, and D.Z. Chang Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II Study J Clin Oncol 26 2008 4311 4318
30. J.M. Lee, G.A. Sarosy, and C.M. Annunziata Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity Br J Cancer 102 2010 495 499
31. J.A. Sosman, K.T. Flaherty, and M.B. Atkins Updated results of phase I trial of sorafenib (D) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC) J Clin Oncol 26 2008 [Suppl.; abstr 5011]
32. J.M. Hubbard, S.R. Alberts, and W.S. Loui Phase I evaluation of sorafenib (SOR) and bevacizumab (BEV) as first-line therapy in hepatocellular cancer (HCC): North Central Cancer treatment Group trial N0745 J Clin Oncol 29 2011 [Suppl.; abstr 4116]
33. B. Escudier, T. Einsen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
34. M.H. Kulke, L.L. Siu, and J.E. Tepper Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting J Clin Oncol 29 2011 934 943